RPL28 antibodies target the ribosomal protein L28, encoded by the RPL28 gene. This protein is part of the large 60S ribosomal subunit and plays a role in mRNA translation, ribosome biogenesis, and stress response . RPL28 antibodies are widely used in molecular biology to study its expression, localization, and function in both normal and diseased states.
RPL28 regulates MHC class I peptide generation by influencing the degradation of defective ribosomal products (DRiPs). Knockdown of RPL28 increases ubiquitin-dependent and -independent antigen presentation, suggesting its role in modulating immune surveillance .
Structural proximity to RPL6 on the ribosome allows RPL28 to influence rRNA methylation patterns (e.g., Am2388, Gm4588) and ribosome-associated proteins, altering peptide supply for immune recognition .
RPL28 knockdown increases HLA-A2 surface expression in TAP-dependent and -independent pathways, suggesting its role in peptide generation .
In colorectal cancer, high RPL28 expression alters extracellular matrix and immunoglobulin pathways, promoting tumor progression .
Western Blot: Detects RPL28 at ~16 kDa in HeLa, NIH/3T3, and HT-29 cells .
Immunohistochemistry: Validated in human tissues (e.g., Fallopian tube, lymphoid) .
Here’s a structured FAQ collection for RPL28 antibody research, prioritizing experimental design, methodological rigor, and data interpretation:
RPL28 is a component of the 60S ribosomal subunit, directly involved in mRNA decoding and peptide bond formation . Antibodies against RPL28 enable:
Localization studies: Tracking ribosomal distribution in subcellular compartments (e.g., cytoplasm, exosomes) .
Expression profiling: Correlating RPL28 levels with cellular growth or stress responses using Western blot (WB) or immunofluorescence (IF) .
Validation: Confirming CRISPR/Cas9 knockdown efficiency by comparing protein levels to controls .
Validation requires a multi-step approach:
Positive controls: Use tissues/cell lines with confirmed RPL28 expression (e.g., HT-29, mouse liver) .
Knockdown validation: Compare signal intensity in siRNA-treated vs. wild-type samples .
Immunogen alignment: Verify antibody epitope matches the target sequence (e.g., residues 1–100 in human RPL28) .
Cross-reactivity checks: Test against lysates from non-target species (e.g., rat spleen vs. human cell lines) .
Inconsistent results often arise from:
Post-translational modifications: RPL28 isoforms or phosphorylation may alter epitope accessibility .
Fixation artifacts: Prolonged formaldehyde fixation masks epitopes in IHC; optimize antigen retrieval .
Ribosomal heterogeneity: Antibodies may preferentially bind free RPL28 vs. ribosome-bound forms .
Solution: Perform parallel experiments with:
Alternative antibodies: Compare clones targeting different epitopes (e.g., N-terminal vs. C-terminal) .
Ribosome profiling: Combine IF with sucrose density centrifugation to isolate ribosomal fractions .
Pre-absorption: Incubate antibody with blocking peptides (e.g., immunogen sequence: MSAHLQWMVVRNCSSFLIKR...) .
Signal amplification: Use tyramide-based systems for IF in tissues with endogenous RNase activity .
Buffer optimization: Include 0.1–0.3% Tween-20 to reduce non-specific binding in WB .
Crosslinking IP-MS: Identify RPL28 interaction partners using formaldehyde fixation and mass spectrometry .
Spatial transcriptomics: Correlate IF-stained RPL28 localization with mRNA expression patterns .
Negative controls:
Loading controls: GAPDH or β-actin for WB; histone H3 for nuclear/cytoplasmic splits .